Medical professionals representing hospital systems from across the United States are expected to attend the first National Cardiogenic Shock Initiative (NCSI) meeting Oct. 29 in Denver. The gathering will help kick off Transcatheter Cardiovascular Therapeutics (TCT) 2017, an annual educational meeting specializing in interventional cardiovascular medicine.

Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 29-Nov. 2 in Denver, on the company’s full line of sirolimus-eluting bioresorbable scaffold (BRS) products during a satellite breakfast meeting and in an oral presentation on Oct. 31.

Philips recently announced the key findings of its research focused on the patient experience in diagnostic imaging procedures. Philips’ Patient Experience in Imaging Study surveyed 603 patients in the United States and Germany about their satisfaction, expectations, preferences and unmet needs with diagnostic imaging procedures in the past year. Patients identified trust in the referring doctor, communication, comfort, safety and getting the image right the first time as key priorities. The research provides insight into how patients perceive imaging procedures, what they value during the process, and what healthcare professionals can do to create a more patient-centered imaging experience.

October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies ...

October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.7 ...

October 23, 2017 — The first patient implant has taken place in the APOLLO Trial, the pivotal trial designed to evaluate ...

The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation Center in Boston. The Center will be home to the Cardiovascular Medicine Innovation team, led by Calum MacRae, M.D., Ph.D., chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH) who, leveraging the latest technologies and scientific advances, will continue their work for One Brave Idea, the $75 million research enterprise charged with bringing an end to coronary heart disease and its consequences.